This study explores how β-catenin<sup>S33Y</sup>-mutated HCC activates OXCT1 to reprogram ketone body metabolism to drive HCC ketogenic therapy resistance and metastasis. The gene discussed is OXCT1; the disease is hepatocellular carcinoma.